CXCR4-S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstr¨om macroglobulinemia

Joshua N. Gustine, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, and Jorge J. Castillo

CXCR4-S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstr¨om macroglobulinemia

Submitted 28 June 2019; accepted 20 August 2019. DOI 10.1182/bloodadvances.2019000635